“Cancer Testis Antigen (CTA) T21, as a Potential Diagnostic, Prognostic, and Immune-Therapeutic Targets for Malignant Tumours”., joms, vol. 17, no. 1, pp. 1–7, Jan. 2022, doi: 10.51984/joms.v17i1.1892.